newsfilter
← Latest News
GlobeNewswire·

C4 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Cemsidomide Phase 2 MOMENTUM Trial On Track to Complete Enrollment in 1Q 2027 with Initial ORR Data Expected in 2H 2027 Enrollment Complete for First Safety Cohort in Phase 1b Trial of Cemsidomide with Elranatamab;